Anticoagulation Safety

Etiology

The etiology of anticoagulation-related complications is multifactorial and reflects interactions among drug pharmacology, patient comorbidities, concurrent medications, and systems-level factors that affect prescribing, monitoring, and follow-up. Complications generally result from either excess anticoagulant effect, which increases bleeding risk, or insufficient anticoagulation, which predisposes patients to recurrent thrombosis, stroke, or thromboembolism.[1][2]

Major contributors to anticoagulant-related complications include the following:

Drug-Specific Factors

Warfarin is affected by dietary vitamin K intake, hepatic metabolism, and genetic variation in cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase complex subunit 1 (VKORC1) genes. See StatPearls’ companion reference, "Warfarin Drug Interactions," for more in-depth discussion of drug-drug interactions. DOAC exposure is influenced by renal clearance, hepatic metabolism, and transporter-mediated effects such as P-glycoprotein activity. Clinically important drug interactions with DOACs are driven mainly by effects on P-glycoprotein and the CYP3A4 enzyme, as well as by additive impairment of hemostasis from other antithrombotic agents. Because DOAC plasma concentrations correlate with both bleeding and thrombotic outcomes, unrecognized interactions that increase or decrease drug levels can alter risk. 

Drugs that increase DOAC levels and increase bleeding risk:

• Strong dual P-glycoprotein and CYP3A4 inhibitors: Azole antifungals (ketoconazole, itraconazole), HIV protease inhibitors, and some hepatitis C antivirals can markedly increase apixaban and rivaroxaban concentrations; these combinations are generally avoided or require dose reduction and close monitoring.
• Potent P-glycoprotein inhibitors affecting dabigatran and edoxaban: Dronedarone, verapamil (especially immediate-release given near the DOAC dose), amiodarone, and certain macrolides increase dabigatran or edoxaban exposure; label-based dose reduction or avoidance is recommended in patients with renal impairment.
• Antiplatelet agents and nonsteroidal anti-inflammatory drugs: Aspirin, purinergic P2Y12 receptor inhibitors, and nonsteroidal anti-inflammatory drugs increase bleeding risk with all DOACs via a pharmacodynamic interaction, even when pharmacokinetics are unchanged.[3][4]

Drugs that decrease DOAC levels and increase thrombosis risk:

• Strong CYP3A4 and P-glycoprotein inducers, including rifampin, carbamazepine, phenytoin, phenobarbital, primidone, and St. John’s Wort, can significantly lower DOAC concentrations and should usually be avoided.
• Some antiepileptics, including valproate and possibly levetiracetam, may reduce DOAC exposure through less well-defined mechanisms and warrant cautious use and specialist input.[3]

Patient-Related Risk Factors

Advanced age, frailty, chronic kidney disease, liver disease, thrombocytopenia, active cancer, prior bleeding, and uncontrolled hypertension increase the risk of hemorrhagic complications regardless of the anticoagulant used.[5][6]

Structural and Disease-Specific Conditions

Cerebral amyloid angiopathy, peptic ulcer disease, vascular malformations, and other lesions that impair vascular integrity increase the likelihood of major or site-specific bleeding, particularly intracranial or gastrointestinal tract hemorrhage.[7]

Adherence and Dosing Problems

Missed doses, inappropriate dose reduction, duplicate therapy, premature discontinuation, and poor follow-up can lead to recurrent venous thromboembolism, cardioembolic stroke, or apparent anticoagulant failure.[8][9]

Systems-Level Contributors

Inadequate medication reconciliation, failure to monitor renal function, inconsistent periprocedural planning, fragmented communication, and insufficient patient education frequently contribute to preventable anticoagulant-related harm.[10][11] Overall, anticoagulation complications arise not only from the anticoagulant itself but also from patient-related factors, the burden of interactions, and gaps in coordinated care.

Epidemiology

Given their efficacy and more favorable safety profile, DOACs have become the preferred choice over vitamin K antagonists for stroke prevention in atrial fibrillation and venous thromboembolism, 2 of the most common reasons for long-term anticoagulation. The 2023 American College of Cardiology, American Heart Association, American College of Clinical Pharmacy, and Heart Rhythm Society Guideline recommends DOACs as first-line therapy over warfarin for patients with atrial fibrillation, except in those with moderate-to-severe mitral stenosis or mechanical heart valves. The risk of bleeding-related complications is highest within the first 3 to 6 months of therapy.[12][13][14]

Bleeding Risk: DOACs Versus Warfarin

DOACs are associated with a lower overall risk of major bleeding, primarily driven by a consistent approximately 50% reduction in intracranial hemorrhage compared with warfarin. The annual risk of intracranial hemorrhage with DOACs is low, approximately 0.2% to 0.4%, but remains clinically significant given the high mortality associated with anticoagulant-related intracerebral hemorrhage.[15] In venous thromboembolism, major bleeding rates are lower with DOACs than with warfarin during both initial and extended treatment, with apixaban demonstrating the lowest rates among available agents.[16]

However, gastrointestinal tract bleeding risk is agent-specific and more variable. Rivaroxaban and higher-dose dabigatran and edoxaban are associated with higher rates of gastrointestinal tract bleeding compared with warfarin, whereas apixaban consistently shows a more favorable gastrointestinal safety profile, with lower bleeding risk across large observational cohorts and real-world datasets.[17] Bleeding risk increases with age and comorbidity burden. Key risk factors for anticoagulant-related bleeding include advanced age, hypertension, prior stroke, concomitant antiplatelet use, cerebral amyloid angiopathy, and renal dysfunction. Although the relative safety advantage of DOACs may diminish in older patients, they continue to offer significant reductions in intracranial hemorrhage and comparable or improved overall outcomes compared with warfarin.

In frail older adult populations, DOACs, particularly apixaban, demonstrate favorable efficacy and safety, with reduced stroke, intracranial bleeding, and mortality. However, the risk of gastrointestinal tract bleeding may remain elevated in certain subgroups, highlighting the need for individualized anticoagulant selection.[18][19] In summary, DOACs provide a more favorable bleeding profile than warfarin, though differences between agents and patient-specific risk factors should guide clinical decision-making.

Pathophysiology

Anticoagulant-related complications reflect disruption of the tightly regulated hemostatic balance among endothelium, platelets, coagulation factors, and fibrinolysis. These agents reduce thrombin generation or activity to prevent thrombosis, but complications arise when inhibition is excessive, misapplied, or occurs in patients with underlying vulnerabilities. Vitamin K antagonists, including warfarin, inhibit the synthesis of clotting factors II, VII, IX, and X, as well as proteins C and S. The early decline in protein C levels creates a transient prothrombotic state, necessitating bridging therapy in acute thrombosis. At steady state, excessive anticoagulation reduces multiple clotting factors, impairing fibrin formation and predisposing to major bleeding, including intracranial and gastrointestinal tract hemorrhage.

Direct oral anticoagulants target specific steps in the coagulation cascade. Direct thrombin inhibitors, including dabigatran, block factor IIa, while factor Xa inhibitors, including apixaban, rivaroxaban, and edoxaban, reduce thrombin generation. Although pharmacokinetically predictable, excess exposure, including from renal dysfunction or drug interactions, similarly impairs stable clot formation and increases bleeding risk. Bleeding risk depends not only on the intensity of anticoagulation but also on local vascular pathology. Conditions such as hypertension and cerebral amyloid angiopathy predispose patients to intracranial hemorrhage, while gastrointestinal tract lesions, including ulcers, angiodysplasia, and cancer, increase the risk of overt bleeding. Confined spaces, including the spinal canal, amplify the clinical impact of even small hematomas.

Nonhemorrhagic complications include anticoagulant-related nephropathy, which involves glomerular hemorrhage with tubular obstruction by red blood cell casts; cholesterol crystal embolization from dissolution of protective thrombus overlying ulcerated aortic plaques; and complications specific to vitamin K antagonists, including accelerated vascular calcification, intraplaque hemorrhage promoting plaque vulnerability, warfarin-induced skin necrosis, and purple toe syndrome.[20][21] Conversely, inadequate anticoagulation permits thrombin propagation, resulting in recurrent venous thromboembolism, cardioembolic stroke, or prosthetic valve thrombosis. Overall, complications arise from an imbalance between coagulation inhibition and patient-specific structural and systemic risk factors, determining whether bleeding or thrombosis predominates.

History and Physical

The history should first determine why the patient is taking anticoagulation, which agent is being used, and whether the current problem suggests bleeding, thrombosis, or both. Important historical details include the specific anticoagulant, dose, time of the last dose, recent dose changes, missed doses, recent procedures, trauma, falls, and prior bleeding or thromboembolic events. A careful medication review should identify antiplatelet agents, nonsteroidal anti-inflammatory drugs, herbal products, and drugs that alter warfarin or DOAC levels.[22] Symptoms of bleeding may be overt or subtle. Patients should be asked about epistaxis, gingival bleeding, easy bruising, hematuria, melena, hematemesis, heavy menstrual bleeding, back or flank pain, dyspnea, and new severe headache or neurologic symptoms. The history should also assess renal disease, liver disease, thrombocytopenia, cancer, alcohol use, and adherence problems because these factors may increase either bleeding risk or treatment failure.

The physical examination should focus on hemodynamic stability, the source of bleeding, and signs of thrombosis or neurologic compromise. Vital signs may show hypotension, tachycardia, tachypnea, or hypoxia in patients with significant blood loss or thromboembolic complications. General inspection may reveal pallor, diaphoresis, ecchymoses, petechiae, or expanding hematomas. A focused neurologic examination is essential in any patient with headache, confusion, weakness, sensory change, or back pain because anticoagulation increases the risk of intracranial and spinal epidural hemorrhage. Cardiopulmonary examination may identify signs of tamponade, hemothorax, pulmonary embolism, or hypovolemia, while abdominal and rectal examination may reveal tenderness, distension, occult gastrointestinal tract bleeding, or retroperitoneal hemorrhage. The extremities should be assessed for swelling, asymmetry, compartment firmness, pain with passive stretch, pulse deficits, or unilateral tenderness, which may suggest deep venous thrombosis, extremity ischemia, or compartment syndrome.

Certain findings may point to anticoagulant-specific complications. Skin necrosis associated with vitamin K antagonists presents with petechiae that progress to ecchymoses and hemorrhagic bullae, culminating in necrosis and slow-healing eschar formation. Patients with anticoagulant-related nephropathy may present with hypertension, hematuria, signs of volume overload, and reduced urine output.[23] Livedo reticularis, gangrene, cyanosis, skin ulcers, purpura or petechiae, and firm, painful erythematous nodules are the most common clinical findings associated with cholesterol crystal emboli. Acute kidney injury is a common finding. Gastrointestinal tract emboli cause abdominal pain, diarrhea, and occasionally bleeding. Central nervous system emboli may cause amaurosis fugax, transient ischemic attack, stroke, a confusional state, headache, and dizziness.

Evaluation

DOACs are now the preferred oral anticoagulants for many patients with atrial fibrillation and venous thromboembolism, given their ease of use and lower risk of intracranial bleeding compared with warfarin.[12][24] However, safe prescribing requires clearly differentiating absolute or near-absolute contraindications, situations where DOACs are not preferred, and cases of apparent treatment failure, which often reflect modifiable clinical factors rather than true drug inefficacy (see Table 1). Even in the absence of formal contraindications, warfarin or low-molecular-weight heparin (LMWH) may be more appropriate in selected clinical scenarios.[25]

Absolute Contraindications to DOACs

• Mechanical heart valves: The RE-ALIGN trial demonstrated increased thromboembolic and bleeding complications with dabigatran compared with warfarin.[26] The safety of factor Xa inhibitors has not been established in this population; therefore, warfarin remains the only recommended oral anticoagulant.[25]
• Thrombotic antiphospholipid syndrome: A meta-analysis of randomized trials showed a significantly higher risk of arterial thrombotic events with DOACs compared with vitamin K antagonists, primarily driven by increased stroke risk. This finding was consistent across patient subgroups. Vitamin K antagonists are the preferred therapy.[27]
• Moderate to severe rheumatic mitral stenosis: Patients with rheumatic mitral valve disease were excluded from pivotal DOAC trials, and current guidelines recommend warfarin as the anticoagulant of choice.[12]
• Pregnancy and breastfeeding: DOACs cross the placenta and are detectable in breast milk. Available data suggest increased risks of miscarriage and fetal anomalies. LMWH is preferred during pregnancy, while warfarin or LMWH may be used during breastfeeding.[28]

Strong Caution: Warfarin Generally Preferred

• Postbariatric surgery:  Altered gastrointestinal tract anatomy can significantly impair DOAC absorption, with studies showing subtherapeutic drug levels in a substantial proportion of patients. Warfarin is often preferred because international normalized ratio (INR) monitoring ensures therapeutic anticoagulation. In the immediate postoperative setting, parenteral anticoagulation with LMWH or fondaparinux is recommended, particularly after highly malabsorptive procedures.[29]
• Severe chronic kidney disease (creatinine clearance <30 mL/min) or dialysis:  Patients with advanced renal dysfunction were largely excluded from DOAC trials. Dabigatran is contraindicated in patients with creatinine clearance less than 30 mL/min, and edoxaban is not recommended for patients on dialysis. Although apixaban is labeled for use in end-stage renal disease, the evidence is primarily observational. Anticoagulation decisions in this population should involve shared decision-making.[25]
• Significant drug interactions: Strong CYP3A4 and P-glycoprotein inducers, such as carbamazepine and phenytoin, can reduce DOAC efficacy and increase thrombotic risk, whereas inhibitors can increase bleeding risk. When such interactions cannot be avoided, warfarin is generally preferred because its effect is monitorable.[25]

Use With Caution: Individualized Assessment Required

• Liver disease: DOACs may be used in mild to moderate hepatic impairment (Child-Pugh score A to B), with a lower bleeding risk than warfarin. However, rivaroxaban should be avoided in those with a Child-Pugh score B because of increased drug exposure, and all DOACs are generally contraindicated in Child-Pugh score C, in which warfarin remains the only option.[30]
• Class 3 obesity (body mass index ≥40 kg/m²): Current evidence supports the use of DOACs, particularly apixaban and rivaroxaban, at standard doses regardless of body weight. However, dabigatran and edoxaban should be avoided due to limited supporting data.[25][31]
• Low body weight (≤60 kg): DOACs remain effective and safe when used with appropriate dose adjustments. Edoxaban requires dose reduction in this population, and adherence to labeling recommendations is essential for optimal outcomes.[32][33][34]
• Thrombosis at unusual sites: Evidence for DOAC use in unusual-site thrombosis is evolving and largely observational. DOACs are increasingly used for cerebral venous sinus thrombosis, splanchnic vein thrombosis, left ventricular thrombus, and upper-extremity deep vein thrombosis, with generally favorable safety and efficacy profiles. However, for rarer sites such as ovarian, renal, and retinal vein thrombosis, evidence remains limited, and treatment decisions should be individualized in consultation with specialists.[35][36][37]

Table 1. Anticoagulant Selection for Atrial Fibrillation and Venous Thromboembolism

Abbreviations: ACC/AHA, American College of Cardiology/American Heart Association; AF, atrial fibrillation; APS, antiphospholipid syndrome; BMI, body mass index; CKD, chronic kidney disease; CrCl, creatinine clearance; DOAC, direct oral anticoagulant; ESKD, end-stage kidney disease; GI, gastrointestinal; GU, genitourinary; ICH, intracranial hemorrhage; INR, international normalized ratio; LMWH, low-molecular-weight heparin; RCT, randomized controlled trial; TTR, time in therapeutic range; VKA, vitamin K antagonist; VTE, venous thromboembolism.

Apparent DOAC Failure and Recurrent Thrombosis 

Recurrent thrombosis during DOAC therapy should be interpreted with caution, because true anticoagulant failure is uncommon, occurring in approximately 2% of treated patients, with similar rates observed with DOACs and vitamin K antagonists.[13] Before labeling treatment failure, clinicians should confirm true recurrence with appropriate imaging and distinguish it from residual thrombosis or alternative diagnoses. Current guidelines recommend objective confirmation, with recurrence defined by involvement of a previously unaffected vascular territory.[13]

Once recurrence is established, a structured evaluation should focus on identifying modifiable contributors (see Image. Clinical Approach to Recurrent Thrombosis With DOAC Therapy). Common factors include nonadherence, inappropriate dose reduction, drug interactions, impaired absorption, and changes in renal function. Off-label underdosing is particularly important because it is associated with increased thromboembolic risk and mortality without a reduction in bleeding. Concomitant use of CYP3A4 or P-glycoprotein inducers may reduce DOAC exposure, while gastrointestinal tract conditions or prior surgical procedures can impair absorption. Additionally, underlying prothrombotic states, including cancer, antiphospholipid syndrome, or severe thrombophilia, should be considered.[13][47] Although routine monitoring of DOAC levels is not recommended, measurement may be helpful in selected clinical scenarios, including suspected treatment failure, extremes of body weight, or potential drug interactions. Both low and high drug levels have been associated with increased risks of thrombosis and bleeding, respectively.[48]

If recurrent thrombosis occurs despite confirmed therapeutic anticoagulation, current guidelines recommend transitioning to an alternative anticoagulant, typically a parenteral agent such as LMWH or fondaparinux, rather than switching between DOACs. Specialist consultation is advised in complex cases, particularly when recurrence occurs in the context of cancer, antiphospholipid syndrome, or significant renal or gastrointestinal impairment.[25][47] Mechanistically, DOAC failure in certain conditions may relate to their single-target inhibition of factor Xa or thrombin, in contrast to the broader anticoagulant effect of vitamin K antagonists. This distinction may be clinically relevant in disorders driven by intrinsic pathway activation, such as antiphospholipid syndrome or device-related thrombosis.[25]

Treatment / Management

Anticoagulation Reversal

Management of major bleeding in patients taking anticoagulants begins with immediate cessation of anticoagulants and antiplatelet agents when feasible, along with hemodynamic stabilization, local bleeding control, and transfusion support. Reversal should be reserved for life-threatening, uncontrolled, or critical-site bleeding, or when urgent procedures are required, given the associated thromboembolic risk.

Reversal strategies are agent-specific:

• Unfractionated heparin is reversed with protamine sulfate, administered at 1 mg per 100 units of heparin given in the preceding 2 to 3 hours (maximum 50 mg), infused slowly (≤5 mg/min). Repeat dosing of 0.5 mg per 100 units may be given if the activated partial thromboplastin time remains elevated.[42][49]
• Low-molecular-weight heparin is only partially reversible; protamine is given as 1 mg per 1 mg enoxaparin within 8 hours, or 0.5 mg per 1 mg if 8 to 12 hours have elapsed, with consideration of a repeat dose in ongoing bleeding.[42][49]
• Fondaparinux has no specific antidote; management is supportive, although recombinant factor VIIa (90 μg/kg) may be considered in life-threatening bleeding despite limited evidence.[49][50]
• For warfarin-associated bleeding, guidelines recommend 4-factor prothrombin complex concentrate at 50 U/kg intravenously, combined with intravenous vitamin K (5–10 mg), to achieve rapid and sustained reversal. Fresh-frozen plasma is an alternative when 4-factor prothrombin complex concentrate is unavailable, but it is less effective and associated with volume overload.[12][51]
• Reversal of DOACs depends on the specific agent. Dabigatran is reversed with idarucizumab (5 g intravenous given as 2 separate 2.5 g boluses), which rapidly neutralizes its effect; hemodialysis can remove approximately 60% of the drug in 2–3 hours if needed.[22][52] For factor Xa inhibitors (apixaban, rivaroxaban, edoxaban), 4-factor prothrombin complex concentrate at 50 U/kg IV is currently the primary reversal strategy in the United States following withdrawal of andexanet alfa, which demonstrated improved hemostasis but higher thrombotic risk without mortality benefit. Activated 4-factor prothrombin complex concentrate may be considered selectively. Adjunctive measures include activated charcoal administered within 2 to 4 hours of DOAC ingestion and supportive care tailored to the severity of bleeding.[53] Emerging agents such as ciraparantag, a potential universal reversal agent, are under investigation.[54]
(A1)

Overall, anticoagulation reversal requires a careful balance between rapid hemostasis and thrombotic risk, and should follow standardized institutional protocols whenever possible.

Resumption of Anticoagulation After Bleeding

Standardized bleeding definitions are essential for consistent reporting in anticoagulation studies. The International Society on Thrombosis and Hemostasis classification categorizes bleeding into major, clinically relevant nonmajor, and minor. Major bleeding includes fatal events, bleeding in critical organs, a hemoglobin drop of at least 2 g/dL, or transfusion of at least 2 units of blood. Clinically relevant nonmajor bleeding refers to overt bleeding that requires medical attention, hospitalization, or a change in therapy but does not meet the major criteria. In contrast, minor bleeding includes self-limited events that do not require intervention.[22](B3)

In patients who experience major bleeding, resumption of anticoagulation is often associated with a net clinical benefit once the bleeding source is controlled. The decision should be individualized based on thrombotic and bleeding risks, as well as the underlying indication for anticoagulation. In general, guidelines suggest resuming therapy between 2 weeks and 90 days after a major bleed, with earlier resumption considered in high thrombotic risk patients, sometimes using short-acting agents such as unfractionated heparin.[22](B3)

Timing varies by bleeding site. After gastrointestinal tract bleeding, resumption within 7 days is associated with reduced thromboembolism and mortality despite a modest increase in recurrent bleeding risk.[55] Intracranial hemorrhage requires a more cautious approach, with resumption typically delayed to 4 to 8 weeks, or longer in patients at high risk of recurrence, such as those with cerebral amyloid angiopathy. Results from emerging randomized trial data suggest that restarting anticoagulation after intracranial hemorrhage reduces ischemic events without a clear increase in recurrent bleeding, although evidence remains limited.[51][56] In selected patients, particularly those with high rebleeding risk or uncertain indications, delayed resumption or alternative strategies such as left atrial appendage occlusion may be appropriate.[57] Overall, decisions regarding anticoagulation resumption should incorporate clinical context, imaging findings, and patient preferences, emphasizing an individualized approach.(A1)

Periprocedural Management

Periprocedural management of DOACs should follow a standardized, pharmacokinetic-based approach guided by procedural bleeding risk, renal function, and the specific agent. Results from the PAUSE study supported simple interruption strategies without heparin bridging or routine drug-level testing, demonstrating low rates of thromboembolism and major bleeding. Accordingly, routine preoperative DOAC level measurement is not recommended for elective procedures, although measurement may be useful in urgent settings to guide reversal decisions.[58]

In general, DOACs are held 1 day before low to moderate-risk bleeding procedures and 2 days before high-risk procedures, with a longer interruption required in renal impairment, particularly for dabigatran. DOACs should be taken on the day of the surgical procedure. For neuraxial procedures, more conservative interruption is required, typically more than 3 days for factor Xa inhibitors and more than 4 days for dabigatran, because of the risk of spinal hematoma.[58]

Heparin bridging is not recommended because DOACs have short half-lives and a rapid onset of action, and bridging increases bleeding risk without reducing thromboembolic risk. Postoperatively, DOACs are generally resumed 24 hours after low-risk procedures and 48 to 72 hours after high-risk procedures, once hemostasis is attained. In patients at high thrombotic risk with delayed DOAC resumption, short-term prophylactic-dose LMWH may be considered.[58]

Differential Diagnosis

The differential diagnosis in patients taking anticoagulation depends on the presenting symptom and on whether the concern is bleeding, thrombosis, or another process that mimics either. Anticoagulation may worsen bleeding from an existing lesion, but clinicians should not automatically assume anticoagulation is the sole cause of the presentation.

Suspected Gastrointestinal Bleeding

• Peptic ulcer disease
• Gastrointestinal malignant tumors
• Angiodysplasia or vascular ectasia
• Diverticular bleeding, colitis, or hemorrhoidal bleeding
• Portal hypertensive bleeding in patients with liver disease

Hematuria or Genitourinary Tract Bleeding

• Urinary tract infection
• Nephrolithiasis
• Bladder or renal malignant neoplasm.
• Glomerulonephritis or other intrinsic renal disease

Acute Neurologic Symptoms

• Intracranial hemorrhage related to anticoagulation
• Ischemic stroke or transient ischemic attack
• Subarachnoid hemorrhage
• Brain mass lesion
• Migraine, seizure, or metabolic encephalopathy

Back Pain With Weakness or Sensory Change

• Spinal epidural hematoma, especially in patients receiving anticoagulation
• Spinal abscess
• Disc herniation
• Vertebral fracture
• Metastatic spinal cord compression

Chest Pain, Dyspnea, or Tachycardia

• Pulmonary embolism from treatment failure
• Acute coronary syndrome
• Heart failure exacerbation
• Pneumonia
• Hemothorax or hemopericardium
• Anxiety or other noncardiopulmonary causes

Limb Pain or Swelling

• Deep venous thrombosis despite therapy
• Cellulitis
• Superficial thrombophlebitis
• Venous insufficiency or lymphedema
• Trauma-related hematoma
• Compartment syndrome

Unexplained Anemia

• Occult gastrointestinal tract blood loss
• Iron deficiency
• Hemolysis
• Vitamin B12 or folate deficiency
• Bone marrow disease
• Chronic kidney disease or anemia of chronic inflammation

Differential Diagnoses for Warfarin-Induced Skin Necrosis 

• Necrotizing fasciitis
• Venous gangrene (eg, phlegmasia cerulea dolens)
• Heparin-induced thrombocytopenia with thrombosis
• Disseminated intravascular coagulation
• Purpura fulminans (eg, severe sepsis, congenital or acquired protein C deficiency)
• Calciphylaxis (uremic or nonuremic)
• Extensive hematoma or cellulitis
• Pyoderma gangrenosum or other neutrophilic dermatoses
• Cholesterol crystal embolization (blue toe or livedo with intact pulses)

Prognosis

Direct oral anticoagulants generally have a more favorable prognosis after anticoagulant-related major bleeding compared with warfarin. Meta-analytic data findings from large phase 3 trials demonstrate lower case-fatality rates with DOACs (7.6% vs 11.0%), along with significant reductions in fatal bleeding, cardiovascular mortality, and all-cause mortality. This advantage is primarily driven by a substantially lower incidence of intracranial hemorrhage (approximately 50% lower than with warfarin), smaller hematoma volumes, and less severe neurologic injury.[59] Results from large observational cohorts further support lower in-hospital mortality with DOAC-associated intracranial hemorrhage, although some studies show comparable outcomes when patients with similar anticoagulant intensity are analyzed, suggesting a potential contribution of selection bias.[60]

In contrast, outcomes following gastrointestinal bleeding are more heterogeneous and appear to be agent-specific. Overall mortality after gastrointestinal tract bleeding is similar between DOACs and warfarin; however, DOAC resumption is associated with lower risks of recurrent bleeding and composite adverse outcomes. Among individual agents, apixaban consistently demonstrates the most favorable bleeding profile, with lower rates of both major bleeding and gastrointestinal bleeding compared with rivaroxaban and warfarin, a finding now supported by head-to-head randomized trial data. Conversely, rivaroxaban and higher-dose dabigatran and edoxaban have been associated with increased gastrointestinal tract bleeding risk.[61] Overall, the survival advantage of DOACs reflects a combination of reduced intracranial hemorrhage, lower rates of fatal bleeding, and, in many cases, less severe bleeding presentations. However, this benefit is not uniform across all bleeding types, and outcomes may be comparable in certain high-risk subgroups.

Complications

Complications of anticoagulant therapy include both hemorrhagic and nonhemorrhagic events. Major bleeding remains the most clinically important complication and may present as intracranial, gastrointestinal tract, retroperitoneal, intra-articular, intramuscular, or spinal and epidural hemorrhage; intracranial and intraspinal bleeding carry the highest risk of death and permanent neurologic disability. Anticoagulant interruption, underdosing, nonadherence, and drug interactions may also result in thromboembolic complications, including recurrent venous thromboembolism, cardioembolic stroke, and valve thrombosis in high-risk patients.

Warfarin-specific complications include skin necrosis, cholesterol embolization, teratogenicity, vascular calcification, and anticoagulant-related nephropathy. Direct oral anticoagulants are generally associated with fewer intracranial bleeding events than warfarin. However, DOACs may still cause significant gastrointestinal tract bleeding and can produce nonhemorrhagic adverse effects such as dyspepsia, particularly with dabigatran, and rare renal or hepatic injury. In patients undergoing neuraxial procedures, spinal epidural hematoma is a rare but extremity- and life-threatening complication that should be suspected in any patient taking an anticoagulant with acute back pain, weakness, sensory loss, or urinary retention.